Gadomer-enhanced MR imaging in the detection of microvascular obstruction: Alleviation with nicorandil therapy

Radiology

Volumn 236, Issue 2, 2005, Pages 510-518

  Krombach, Gabriele A ^a,c   Higgins, Charles B ^a   Chujo, Mitsuaki ^b   Saeed, Maythem ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Chugai Pharmaceutical   (Japan)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOMER 17; NICORANDIL; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC IMAGING; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE VOLUME; IMAGE ANALYSIS; MICROVASCULATURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANIMALS; CONTRAST MEDIA; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; GADOLINIUM; MAGNETIC RESONANCE IMAGING; MICROCIRCULATION; NICORANDIL; RATS; VASODILATOR AGENTS;

EID: 22544473588     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2362030847     Document Type: Article

References (55)

1. Asanuma T, Tanabe K, Ochiai K, et al. Relationship between progressive microvascular damage and intramyocardial hemorrhage in patients with reperfused anterior myocardial infarction. Circulation 1997; 96:448-453.
2. Kaul S, Ito H. Microvasculature in acute myocardial ischemia. II. Evolving concepts in pathophysiology, diagnosis, and treatment. Circulation 2004; 109:310-315.
3. Piana R, Paik G, Moscucci M, et al. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 1994; 89:2514-2518.
4. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50:127-134.
5. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br Heart J 1985; 53:363-373.
6. Erbel R, Heusch G. Coronary microembolization. J Am Coll Cardiol 2000; 36:22-24.
7. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101:570-580.
8. Jeremy RW, Links JM, Becker LC. Progressive failure of coronary flow during reperfusion of myocardial infarction: documentation of the no reflow phenomenon with position emission tomography. J Am Coll Cardiol 1990; 16:695-704.
9. Schwitter J, Saeed M, Wendland MF, et al. Influence of severity of myocardial injury on the distribution of macromolecules: extravascular versus intravascular gadolinium-based magnetic resonance contrast agents. J Am Coll Cardiol 1997; 30:1086-1094.
10. Bremerich J, Wendland MF, Arheden H, et al. Microvascular injury in reperfused infarcted myocardium: noninvasive assessment with contrast enhanced echoplanar magnetic resonance imaging. J Am Coll Cardiol 1998; 32:787-793.
11. Wu KC, Zerhouni E, Judd RM, et al. Prognostic significance of microvascular obstruction magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998; 97:765-772.
12. Rochitte CE, Lima JA, Bluemke DA, et al. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998; 98:1006-1014.
13. Gerber BL, Rochitte CE, Melin JA, et al. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation 2000; 101:2734-2741.
14. Wu KC, Kim RJ, Bluemke DA, et al. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol 1998; 32:1756-1764.
15. Saeed M, van Dijke CF, Mann J, et al. Histologic confirmation of microvascular hyper-permeability to macromolecular MR contrast media in reperfused myocardial infarction. J Magn Reson Imaging 1998; 8:561-567.
16. Krombach GA, Wendland MF, Higgins CB, et al. MR imaging of spatial extent of microvascular injury in reperfused ischemically injured rat myocardium: value of blood pool ultrasmall superparamagnetic particles of iron oxide. Radiology 2002; 225:479-486.
17. Roberts HC, Saeed M, Roberts TP, et al. Comparison of albumin-(Gd-DTPA)30 and Gd-DTPA-24-cascade-polymer for measurements of normal and abnormal microvascular permeability. J Magn Reson Imaging 1997; 7:331-338.
18. Gerber BL, Bluemke DA, Chin BB, et al. Single-vessel coronary artery stenosis: myocardial perfusion imaging with gadomer-17 first-pass MR imaging in a swine model of comparison with gadopentetate dimeglumine. Radiology 2002; 225:104-112.
19. Li D, Zheng J, Weinmann HJ. Contrast-enhanced MRI of coronary arteries: comparison of intra- and extravascular contrast agents in swine. Radiology 2001; 218:670-678.
20. Misselwitz B, Schmitt-Willich H, Ebert W, et al. Pharmacokinetics of gadomer-17, a new dendritic magnetic resonance contrast agent. MAGMA 2001; 12:128-134.
21. Barkhausen J, Herborn C, Bruder O, et al. Contrast-enhanced MR imaging of coronary arteries with gadomer-17 (abstr). J Cardiovasc Magn Reson 2003; 5:5124.
22. Taniyama Y, Ito H, Iwakura K, et al. Beneficial effects of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30:1193-1199.
23. Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following precutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37:1335-1343.
24. Fischell TA, Carter AJ, Foster MT, et al. Reversal of "no-reflow" during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998; 45:360-365.
25. Taniyama Y, Ito H, Morishita R, et al. Potential of microvascular perfusion with adjunctive pharmacological intervention: its impact on myocardial perfusion and functional outcomes in patients with acute myocardial infarction. Drugs 2001; 61:437-441.
26. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344:1895-1903.
27. Sakata Y, Kodama K, Momamura K, et al. Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J 1997; 133:616-621.
28. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33:654-660.
29. Sugimoto K, Ito H, Iwakura K, et al. Intravenous nicorandil in conjunction with coronary reperfusion therapy is associated with better clinical and functional outcomes in patients with acute myocardial infarction. Circ J 2003; 67:295-300.
30. Sato T, Sasaki N, O'Rourke B, et al. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000; 35:514-518.
31. Watzinger N, Lund GK, Higgins CB, et al. Noninvasive assessment of the effects of nicorandil on left ventricular volumes and function in reperfused myocardial infarction. Cardiovasc Res 2002; 54:77-84.
32. Lund GK, Higgins CB, Wendland MF, et al. Assessment of nicorandil therapy in ischemic myocardial injury by using contrast-enhanced and functional MR imaging. Radiology 2001; 221:676-682.
33. Krombach GA, Higgins CB, Chujo M, et al. Blood pool enhanced MRl detects suppression of microvascular permeability in early post-infarction reperfusion after nicorandil therapy. Magn Reson Med 2002; 47:896-902.
34. Saeed M, Watzinger N, Krombach G, et al. Left ventricular remodeling after infarction: sequential MR imaging with oral nicorandil therapy in rat model. Radiology 2002; 224:830-837.
35. Haager PK, Klues HG, Schmidt M, et al. Effect of nitroglycerin and nicorandil on regional poststenotic quantitative coronary blood flow in coronary artery disease: a combined digital quantitative angiographic and intracoronary Doppler study. J Cardiovasc Pharmacol 1999; 33:126-134.
36. Markham A, Plosker GL, Goa KL. Nicorandil: an update review of its use in ischemic heart disease with emphasis on its cardioprotective effects. Drugs 2000; 60:955-974.
37. Knight C, Purcell H, Fox K. Potassium channel openers: clinical applications in ischemic heart disease: overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 1995; 9(suppl 2):229-236.
38. Hale SL, Kloner RA. Effect of early coronary artery perfusion on infarct development in a model of low collateral flow. Cardiovasc Res 1987; 21:668-673.
39. Gavin JB, Humphrey SM, Herdson PB. The no-reflow phenomenon in ischemic myocardium. Int Rev Exp Pathol 1983; 25:361-383.
40. Schaper W. Experimental infarcts and the microcirculation. In: Hearse DJ, Yellon DM, eds. Therapeutic approaches to myocardial infarct size limitation. New York, NY: Raven, 1984; 79-90.
41. Garcia-Dorado D, Theroux P, Solares J, et al. Determinants of hemorrhagic infarcts: histologic observations from experiments involving coronary occlusion, coronary reperfusion, and reocclusion. Am J Pathol 1990; 137:301-311.
42. Solal AC, Jaeger P, Bouthier J, et al. Hemodynamic action of nicorandil in chronic congestive heart failure. Am J Cardiol 1989; 63(suppl 21):44J-48J.
43. Saeed M, Lund G, Wendland MF, et al. Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis specific and extracellular nonspecific contrast media. Circulation 2001; 103:871-876.
44. Oh BH, Ono S, Rockman HA, et al. Myocardial hypertrophy in the ischemic zone induced by exercise in rats after coronary reperfusion. Circulation 1993; 87:598-607.
45. Weisman HF, Bush DE, Mannisi JA, et al. Global cardiac remodeling after acute myocardial infarction: a study in the rat model. J Am Coll Cardiol 1985; 5:1355-1362.
46. Jain M, DerSimonian H, Brenner DA, et al. Cell therapy attenuates deleterious ventricular remodeling and improves cardiac performance after myocardial infarction. Circulation 2001; 103:1920-1927.
47. Coltart DJ, Signy M. Acute hemodynamic effects of single-dose nicorandil in coronary artery disease. Am J Cardiol 1989; 63(suppl 21):34J-39J.
48. Dauber IM, VanBenthuysen KM, McMurtry IF, et al. Functional coronary microvessel injury evident as increased permeability due to brief ischemia and reperfusion. Circ Res 1990; 66:986-998.
49. Inauen W, Payne DK, Kvietys PR, Granger DN. Hypoxia/reoxygenation increases the permeability of endothelial cell monolayers: role of oxygen radicals. Free Radic Biol Med 1990; 9:219-223.
50. Kloner RA, Rude RE, Carlson N, et al. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation 1980; 62:945-952.
51. Kloner RA. Does repertusion injury exist in humans? J Am Coll Cardiol 1993; 21:537-545.
52. Berdeaux A, Drieu la Rochelle C, Richard V, et al. Differential effects of nitrovasodialtors, K(+)-channel openers and nicorandil on large and small coronary arteries in conscious dogs. J Cardiovasc Pharmacol 1992; 20(suppl 7):S17-S21.
53. Liu Y, Sato T, O'Rourke E, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998; 97:2463-2469.
54. Wang Y, Hirai K, Ashraf M. Activation of mitochondrial ATP sensitive potassium channel for cardiac protection against ischemic injury is dependent on protein kinase C activity. Circ Res 1999; 85:731-741.
55. Horn M, Hugel S, Schroeder M, et al. Mechanisms of the effects of nicorandil in the isolated rat heart during ischemia and reperfusion: a 31P-nuclear magnetic resonance study. J Cardiovasc Magn Reson 2001; 3:349-360.